Brief: Adicet Bio Q2 Basic EPS USD -0.34

ADICET Bio

07/08/2025 21:01

Overview

Adicet Bio reports Q2 net loss of $31.2 mln, $0.34 per share

R&D expenses rise to $28.4 mln, G&A expenses decrease to $6.9 mln

Company reduces workforce by 30% to extend cash runway to Q4 2026

Outlook

Adicet expects preliminary ADI-001 data in 2H/2025

Company plans regulatory filing for ADI-212 in Q1/2026

Adicet anticipates initial ADI-212 data in 2H/2026

Company expects cash runway into Q4/2026

Result Driver

PIPELINE PRIORITIZATION - Strategic review led to discontinuation of ADI-270 and 30% workforce reduction to extend cash runway

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$31.22 mln
Q2 Basic EPS
-$0.34
Q2 Operating Expenses
$32.39 mln
Q2 Operating Income
-$32.39 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Adicet Bio Inc is $6.00, about 88.3% above its August 6 closing price of $0.70

Press Release: ID:nBwbjcGswa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)